dabigatran has been researched along with Hemorrhagic Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sarode, R; Yates, S | 1 |
| Castellino, FJ; Davis, PK; Mitra, R; Musunuru, H; Ploplis, V; Walsh, M | 1 |
1 review(s) available for dabigatran and Hemorrhagic Disorders
| Article | Year |
|---|---|
Novel thrombin and factor Xa inhibitors: challenges to reversal of their anticoagulation effects.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Hemorrhagic Disorders; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2013 |
1 other study(ies) available for dabigatran and Hemorrhagic Disorders
| Article | Year |
|---|---|
The ex vivo reversibility of dabigatran-induced whole-blood coagulopathy as monitored by thromboelastography: mechanistic implications for clinical medicine.
Topics: Antithrombins; Benzimidazoles; Blood Coagulation; Blood Coagulation Factors; Dabigatran; Drug Evaluation, Preclinical; Drug Monitoring; Factor VIIa; Fibrin; Hemorrhagic Disorders; Humans; In Vitro Techniques; Point-of-Care Systems; Pyridines; Recombinant Proteins; Thrombelastography; Thrombin; Whole Blood Coagulation Time | 2012 |